Royalty Pharma (MEX:RPRXN) Research & Development: MXN8,211 Mil (TTM As of Mar. 2026)


MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
72 GF Score
Price MXN775.06
GF Value MXN535.17
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Research & Development?

Royalty Pharma MEX:RPRXN 72 Research & Development is MXN8,211 Mil as of Mar. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Royalty Pharma's Research & Development for the three months ended in Mar. 2026 was MXN718 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN8,211 Mil.

Royalty Pharma  (MEX:RPRXN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Royalty Pharma Research & Development Related Terms

Royalty Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Research & Development Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 4,104.52 3,452.86 882.66 41.71 8,138.58

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,033.14 5,658.18 926.38 909.29 717.52
MEX:RPRXN
72GF Score
Royalty Pharma PLC MEX:RPRXN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN8,211 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN8,211 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Research & Development of MXN8,211 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Research & Development too high?
Royalty Pharma's current Research & Development is MXN8,211 Mil. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Research & Development compare to BNTX and INSM?
Royalty Pharma's Research & Development of MXN8,211 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Research & Development is MXN8,211 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Research & Development of MXN8,211 Mil. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Research & Development is MXN8,211 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Research & Development is MXN8,211 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.

Key valuation signals for MEX:RPRXN:

  • Research & Development: MXN8,211 Mil
  • GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for MEX:RPRXN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN775.06
Price
MXN535.17
GF Value